5 results about "Purinergic receptor" patented technology

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The invention discloses a multi-stimulation device for dysphagia rehabilitation training, and relates to the field of rehabilitation training instruments. According to the multi-stimulation device for dysphagia rehabilitation training, a user can load stimulation liquid with different cold and hot temperatures and various tastes in the liquid containing tank, the variety of the stimulation liquid connected into the guide pipe is changed by rotating the rotary drum, and therefore the stimulation liquid with different temperatures and the stimulation liquid with different tastes can be replaced; a heating wire and a semiconductor chilling plate are additionally arranged on the outer wall of the liquid containing tank, so that the liquid temperature is adjusted bidirectionally, and accurate cold and hot temperature control is achieved; a user can press the pumping assembly to pump the stimulation liquid into the bite pad through the guide pipe and the rotary drum, the stimulation liquid is sprayed out from the end of the massage block, a patient can bite the bite pad to receive alternate stimulation treatment of the stimulation liquid, the stimulation liquid with different tastes or different temperatures is rapidly alternated, a TRPV1 temperature-sensitive ion channel and a P2X3 purine receptor can be effectively activated, and the treatment effect is good. Signal transduction of a swallowing reflex arc is enhanced through double paths, and precise rehabilitation is achieved.

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, alone or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts (“TEVGs”) in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The present invention relates to adamantanyl-substituted benzamide compounds and their use as antagonists of the P2X7 purinoreceptor. The invention further relates to methods for the treatment of disease and conditions associated with the P2X7 purinoreceptor.

The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of diseases and conditions in which modulation of Ca2+-signaling plays a role, such as in some forms of spinocerebellar ataxia, and in diseases and conditions benefiting from mucosal hydration, as for example respiratory diseases and conditions, dry eye, xerostomia.